.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,232,307

« Back to Dashboard

Details for Patent: 6,232,307

Title: Tissue selective compounds in the treatment of ovarian cancer
Abstract:The present invention relates to new 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below: ##STR1##
Inventor(s): Miller; Chris P. (Strafford, PA), Collini; Michael D. (Clifton Heights, PA), Tran; Bach D. (Media, PA), Santilli; Arthur A. (Havertown, PA)
Assignee: American Home Products Corporation (Madison, NJ)
Filing Date:Oct 12, 1999
Application Number:09/416,078
Claims:1. A method of treating or preventing ovarian cancer in a mammal; the method comprising administering to a mammal in need thereof an effective amount of a compound of the formulae: ##STR183##

wherein:

R.sub.1 is selected from H, OH, --O--C(O)-C.sub.1 -C.sub.12 alkyl (straight chain or branched), --O--C.sub.1 -C.sub.12 alkyl (straight chain or branched or cyclic), or halogens; or C.sub.1 -C.sub.4 halogenated ethers,

R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)-C.sub.1 -C.sub.12 (straight chain or branched), --O-C.sub.1 -C.sub.12 (straight chain or branched or cyclic); halogens, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH;

X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen;

n is 2 or 3;

Y is the moiety; ##STR184##

a) R.sub.7 and R.sub.8 are independently selected from the group of H, C.sub.1 -C.sub.6 alkyl, or phenyl optionally substituted by CN, C.sub.1 -C.sub.6 alkyl (straight chain or branched), C.sub.1 -C.sub.6 alkoxy (straight chain or branched), halogen, --OH, --CF.sub.3, or --OCF.sub.3 ; or

b) R.sub.7 and R.sub.8 are concentrated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN--, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or

c) R.sub.7 and R.sub.8 are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl; --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or

d) R.sub.7 and R.sub.8 are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or

e) R.sub.7 and R.sub.8 are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or

f) R.sub.7 and R.sub.8 are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2 --, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, --NO.sub.2, or phenyl optionally substituted with 1-3 (C.sub.1 -C.sub.4)alkyl; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein:

R.sub.1 is selected from H, OH, --O--C(O)--C.sub.4 -C.sub.4 alkyl or --O--C.sub.1 -C.sub.4 alkyl, halogen;

R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, cyano, C.sub.1 -C.sub.6 alkyl, or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH;

X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen;

Y is the moiety ##STR185##

R.sub.7 and R.sub.8 are selected independently from H, C.sub.1 -C.sub.6 alkyl, or combined by --(CH.sub.2).sub.p --, wherein p is an integer of from 2 to 6, so as to form a saturated ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONH(C.sub.1 -C.sub.4), --NH.sub.2, C.sub.1 -C.sub.4 alkylamino, di(C.sub.1 -C.sub.4)alkylamino, --NHSO.sub.2 (C.sub.1 -C.sub.4), --NHCO(C.sub.1 -C.sub.4) or --NO.sub.2 ; or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-ethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-be nzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 in which the compound is is 5-Benzyloxy-2-phenyl-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-1H-indol e or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-be nzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-diisopropylamino-1-yl- ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-butyl-methylamino-1-yl ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-dimethylamino)-ethoxy]-be nzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(2-methyl-piperidin-1- yl)-ethoxyl]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(3-methyl-piperidin-1- yl)-ethoxy]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-[2-(4-methyl-piperidin-1- yl)-ethoxy]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1{4-[2-((cis)-2,6-Dimethyl-pip eridin-1-yl)-ethoxy]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-{4-[2-(1,3,3-trimethyl-6-aza-b icyclo[3.2.1]oct-6-yl)-ethoxy]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 in which the compound is is (1S,4R)-5-Benzyloxy-2-(4-benzyloxy-phenyl)-3methyl{4-[2-(2-Aza-bicyclo[2. 2.1]hept-2-yl)-ethoxy]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

15. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-fluoro-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-ethoxy)-benzy l]-1H-indole or a pharmaceutically acceptable salt thereof.

16. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-fluoro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-be nzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

17. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-chloro-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-be nzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 in which the compound is is 5-Benzyloxy-2-[3,4-methylenedioxy-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl- ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

19. The method of claim 1 in which the compound is is 5-Benzyloxy-2-[4-isopropoxy-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy )-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

20. The method of claim 1 in which the compound is is 5-Benzyloxy-2-[4-methyl-phenyl]-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-be nzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

21. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(3-benzyloxy-phenyl)-3-m ethyl-1H-indole or a pharmaceutically acceptable salt thereof.

22. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-[4-(2-piperidin-1-y l-ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

23. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-3-fluoro-phenyl)-3-methyl-1-[4-(2-azepan-1-yl-e thoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

24. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(3-methoxy-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-3-m ethyl-1H-indole or a pharmaceutically acceptable salt thereof.

25. The method of claim 1 in which the compound is is 5-Benzyloxy-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-trifluoro methoxy-phenyl)-1H-indole or a pharmaceutically acceptable salt thereof.

26. The method of claim 1 in which the compound is is (2-{4-[5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-indol-1-ylmethyl]-pheno xy}-ethyl)cyclohexyl-amine or a pharmaceutically acceptable salt thereof.

27. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-{4-methylpiperazin-1-yl)-eth oxy]-benzyl}-1H-indole or a pharmaceutically acceptable salt thereof.

28. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-benzyloxy-2-(3-methoxy-phenyl)-3-met hyl-1H-indole or a pharmaceutically acceptable salt thereof.

29. The method of claim 1 in which the compound is is 4-{3-Methyl-1-[4-(2-piperindin-1-yl-ethoxy)-benzyl]-1H-indole} (HCl).

30. The method of claim 1 in which the compound is is 4-{3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-2-yl}-phenol hydrochloride (HCl).

31. The method of claim 1 in which the compound is is 3-Methyl-2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)-benzyl]-1H-indol-5-ol (HCl).

32. The method of claim 1 in which the compound is is 4-{5-Methoxy-3-methyl-1-{4-[2-(piperidin-1-yl)-ethoxy]-benzyl}-1H-indol-2- yl}-phenol or a pharmaceutically acceptable salt thereof.

33. The method of claim 1 in which the compound is is 2-(4-methoxy-phenyl)-3-methyl-1-{4-[2-(piperidin-1-yl)-ethoxy]-benzyl}-1H- indol-5-ol or a pharmaceutically acceptable salt thereof.

34. The method of claim 1 in which the compound is is 5-Methoxy-2-(4-methoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben zyl]-1H-indole (HCl).

35. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-methoxy-2-(4-methoxy-phenyl)-3-methy l-1H-indole (HCl).

36. The method of claim 1 in which the compound is is 2-(4-Ethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol or a pharmaceutically acceptable salt thereof.

37. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-ethoxy-phenyl)-3-methyl-1H-indol- 5-ol or a pharmaceutically acceptable salt thereof.

38. The method of claim 1 in which the compound is is 4-{5-Fluoro-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-2-yl} -phenol (HCl).

39. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-3-methyl-2-phenyl-1H-indol-5-ol (HCl).

40. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-pyrolidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol or a pharmaceutically acceptable salt thereof.

41. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol (HCl).

42. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol Acetate Salt.

43. The method of claim 1 in which the compound is is 1-[4-(2-Azocan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol or a pharmaceutically acceptable salt thereof.

44. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-dimethyl-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol or a pharmaceutically acceptable salt thereof.

45. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-diethyl-1-yl-ethoxy)-benzyl]-1H-indo l-5-ol or a pharmaceutically acceptable salt thereof.

46. The method of claim 1 in which the compound is is 1-[4-(2-Dipropylamino-ethoxy)-benzyl)-2-(4-hydroxy-phenyl)-3-methyl-1H-ind ol-5-ol or a pharmaceutically acceptable salt thereof.

47. The method of claim 1 in which the compound is is 1-[4-(2-Dibutylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indo l-5-ol or a pharmaceutically acceptable salt thereof.

48. The method of claim 1 in which the compound is is 1-(4-(2-Diisopropylamino-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H- indol-5-ol or a pharmaceutically acceptable salt thereof.

49. The method of claim 1 in which the compound is is 1-[4-[2-Butyl-methyl-amino)-ethoxy]-benzyl]-2-(4-hydroxy-phenyl)-3-methyl- 1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

50. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(2-methyl-piperidin-1-yl)-ethoxy]-be nzyl}-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

51. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(3-methyl-piperidin-1-yl)-ethoxyl]-b enzyl}-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

52. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(4-methyl-piperidin-1-yl)-ethoxy]-be nzyl}-1H-indol-5-ol (HCl).

53. The method of claim 1 in which the compound is is 1-{4-[2-(3,3-Dimethyl-piperidin-1-yl)-ethoxy]-benzyl}-2-(4-hydroxy-phenyl) -3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

54. The method of claim 1 in which the compound is is 1-{4-[2-((cis)-2,6-Dimethyl-piperidin-1-yl)-ethoxy]-benzyl}-2-(4-hydroxy-p henyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

55. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-1-{4-[2-(4-hydroxy-piperidin-1-yl)-ethoxy]-benzyl}-3- methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

56. The method of claim 1 in which the compound is is (1S,4R)-1-{4-[2-(2-Aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy]-benzyl}-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

57. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[2-(1,3,3-trimethyl-6-aza-bicyclo[3.2. 1]oct-6-yl)-ethoxy]-benzyl}-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

58. The method of claim 1 in which the compound is is 2-(4-Fluoro-phenyl)-3-methyl-1-[4-(2-piperidine-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol (HCl).

59. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxyl)-benzyl]-2-(4-fluoro-phenyl)-3-methyl-1H-indol -5-ol or a pharmaceutically acceptable salt thereof.

60. The method of claim 1 in which the compound is is 2-(3-Methoxy-4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-ben zyl]-1-H-indol-5-ol (HCl).

61. The method of claim 1 in which the compound is is 2-Benzyl[1,3]dioxol-5-yl-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1 H-indol-5-ol (HCl).

62. The method of claim 1 in which the compound is is 2-(4-Isopropoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H -indol-5-ol (HCl).

63. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-isopropoxy-phenyl)-3-methyl-1H-in dol-5-ol (HCl).

64. The method of claim 1 in which the compound is is 2-(4-Cyclopenyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl] -1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

65. The method of claim 1 in which the compound is is 3-Methyl-1-[4-(2-piperidin-1-yl)-ethoxy)-benzyl]-2-(4-trifluoromethyl-phen yl)-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

66. The method of claim 1 in which the compound is is 3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-p-tolyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

67. The method of claim 1 in which the compound is is 2-(4-Chloro-phenyl)-3-methyl-1-[4-(2-piperindin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol (HCl).

68. The method of claim 1 in which the compound is is 2-(2,4-Dimethoxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1 H-indol-5-ol or a pharmaceutically acceptable salt thereof.

69. The method of claim 1 in which the compound is is 2-(3-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol or a pharmaceutically acceptable salt thereof.

70. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(3-hydroxy-phenyl)-3-methyl-1H-indol -5of or a pharmaceutically acceptable salt thereof.

71. The method of claim 1 in which the compound is is 2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benz yl]-1H-indol-5-ol of a pharmaceutically acceptable salt thereof.

72. The method of claim 1 in which the compound is is 2-(3-Fluoro-4-hydroxy-phenyl)-3-methyl-1-[4-(azepan-1-yl-ethoxy)-benzyl]-1 H-indol-5-ol or a pharmaceutically acceptable salt thereof.

73. The method of claim 1 in which the compound is is 2-(3-Methoxy-phenol)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dole-5-ol or a pharmaceutically acceptable salt thereof.

74. The method of claim 1 in which the compound is is 3-Methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-2-(4-trifluoromethoxy-phen yl)-1H-indole-5-ol or a pharmaceutically acceptable salt thereof.

75. The method of claim 1 in which the compound is is 3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-1H-i ndol-5-ol (HCl).

76. The method of claim 1 in which the compound is is 3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol (HCl).

77. The method of claim 1 in which the compound is is 3-Chloro-2-(4-hydroxy-phenyl)-1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-1H-indol -5-ol (HCl).

78. The method of claim 1 in which the compound is is 3-Chloro-2-(4-hydroxy-2-methyl-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benz yl]-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

79. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-ethyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol (HCl).

80. The method of claim 1 in which the compound is is 5-Hydroxy-2-(4-Hydroxy-phenyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-i ndole-3-carbonitrile (HCl).

81. The method of claim 1 in which the compound is is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-5-hydroxy-2-(2-hydroxy-phenyl)-1H-indo le-3-carbonitrile (HCl).

82. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-[4-(2-piperidin-1-yl-ethoxy) -benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

83. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-chloro-1-[4-(2-azepan-1-yl-ethoxy)-be nzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

84. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(2-methyl-4-benzyloxy-phenyl)-3-chloro-1-[4-(2-piperidin-1-y l-ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

85. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-piperidin-1-yl-ethoxy)- benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

86. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-piperidin-1-yl-ethoxy)- benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

87. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-cyano-1-[4-(2-azepan-1-yl-ethoxy)-ben zyl]-1H-indole or a pharmaceutically acceptable salt thereof.

88. The method of claim 1 in which the compound is is Di-propionate of 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol.

89. The method of claim 1 in which the compound is is Di-pivalate of 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol -5-ol.

90. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-1-[4-(3-piperidin-1-yl-propoxy)-benzyl] -3-methyl-1H-indole or a pharmaceutically acceptable salt thereof.

91. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-{4-[3-(piperidin-1-yl)-propoxy]-benzyl}-1H -indol-5-ol or a pharmaceutically acceptable salt thereof.

92. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-1-[3-methoxy-4-(2-piperidin-1-yl-ethoxy)-benzyl]-3-me thyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

93. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-1-[3-methoxy-4-(2-azepan-1-yl-ethoxy)-benzyl]-3-methy l-1H-indol-5-ol or a pharmaceutically acceptable salt thereof.

94. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[3-Methoxy-4-(2-piperidin-1- yl-ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

95. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[2-Methoxy-4-(2-azepan-1-yl- ethoxy)-benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

96. The method of claim 1 in which the compound is is Di-pivalate ester of 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol.

97. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy) -benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

98. The method of claim 1 in which the compound is is 5-Benzyloxy-2-(3-benzyloxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy) -benzyl]-1H-indole or a pharmaceutically acceptable salt thereof.

99. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol or a pharmaceutically acceptable salt thereof.

100. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-in dol-5-ol methiodide.

101. The method of claim 1 in which the compound is is 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-dimethyl-1-yl-ethoxy)-benzyl]-1H-ind ol-5-ol methiodide.

102. A method of treating or preventing ovarian cancer in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of the formulae: ##STR186##

wherein:

R.sub.1 is selected from H, OH, --O--C(O)--C.sub.1 -C.sub.12 alkyl (straight chain or branched), --O--C.sub.1 -C.sub.12 alkyl (straight chain or branched or cyclic), or halogens; or C.sub.1 -C.sub.4 halogenated ethers.

R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--C.sub.1 -C.sub.12 (straight chain or branched), --O--C.sub.1 -C.sub.12 (straight chain or branched or cyclic), halogens, or C.sub.1 -c.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl(straight chain or branched), or trifluoromethyl, with the provision that, when R.sub.1 is H, R.sub.2 is not OH;

X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen;

n is 2 or 3;

Y is the moiety; ##STR187##

wherein:

a) R.sub.7 and R.sub.8 are independently selected from the group of H, C.sub.1 -C.sub.6 alkyl, or phenyl optionally substituted by CN, C.sub.1 -C.sub.6 alkyl (straight chain or branched), C.sub.1 -C.sub.6 alkoxy (straight chain or branched), halogen, --OH, --CF.sub.3, or --OCF.sub.3 ; or

b) R.sub.7 and R.sub.8 are concatenated to form a pyrrolidine ring, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN--, --CONHR, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1 --, --NHCOR.sub.1, or --NO.sub.2 ; or

c) R.sub.7 and R.sub.8 are concatenated to form a piperidine ring, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ; or

d) R.sub.7 and R.sub.8 are concatenated to form an azepan ring, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxy, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ; or

e) R.sub.7 and R.sub.8 are concentrated to form a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 acyloxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulfinyl, C.sub.1 -C.sub.4 alkylsulfonyl, hydroxy (C.sub.1 -C.sub.4)alkyl, --CO.sub.2 H, --CN, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2, --NHSO.sub.2 R.sub.1, --NHCOR.sub.1, or --NO.sub.2 ;

or a pharmaceutically acceptable salt thereof.

103. A method of treating or preventing ovarian cancer in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of the formulae: ##STR188##

wherein:

R.sub.1 is selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers;

R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--(.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -c.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H, R.sub.2 is not OH.

X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen;

n is 2 or 3;

Y is the moiety; ##STR189##

wherein R.sub.7 and R.sub.8 are independently selected from the group of H, C.sub.1 -C.sub.6 alkyl, or phenyl optionally substituted by CN, C.sub.1 -C.sub.6 alkyl (straight chain or branched), C.sub.1 -C.sub.6 alkoxy (straight chain or branched), halogen, --OH, --CF.sub.3, or --OCF.sub.3 ; or R.sub.7 and R.sub.8 are concatenated to form a nitrogen containing heterocycle moiety selected from the group of: ##STR190##

the nitrogen containing heterocycle moiety being optionally substituted by from 1 to 3 groups selected from hydrogen, hydroxy, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 alkylthio, --CN, --CO.sub.2 H, --CONHR.sub.1, --NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2 or --NO.sub.2 ;

or a pharmaceutically acceptable salt thereof.

104. The method of claim 103 wherein R.sub.1 is selected from H, OH, --O-- C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers;

R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from H, OH, --O--C(O)--(C.sub.1 -C.sub.4 alkyl), --O--(C.sub.1 -C.sub.4 alkyl), halogen, or C.sub.1 -C.sub.4 halogenated ethers, cyano, C.sub.1 -C.sub.6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R.sub.1 is H R.sub.2 is not OH;

X is selected from H, C.sub.1 -C.sub.6 alkyl, cyano, nitro, trifluoromethyl, halogen;

n is 2 or 3;

Y is the moiety; ##STR191##

wherein R.sub.7 and R.sub.8 are independently selected from the group of H or C.sub.1 -C.sub.6 alkyl; or R.sub.7 and R.sub.8 are concatenated to form a nitrogen containing heterocyclic moiety of the group; ##STR192##

the nitrogen containing heterocyclic moiety being optionally substituted by from 1 to 3 groups selected from hydrogen, hydroxy, halo, C.sub.1 -C.sub.4 alkyl, trihalomethyl, C.sub.1 -C.sub.4 alkoxy, trihalomethoxy, C.sub.1 -C.sub.4 alkylthio, --CN, --CO.sub.2 H, --CONHR.sub.1 ----NH.sub.2, --NH(C.sub.1 -C.sub.4 alkyl), --N(C.sub.1 -C.sub.4 alkyl).sub.2 or --NO.sub.2 ;

or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc